FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
stimated average burden					
ours per response	e 0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	es)														
I. Name and Address of Reporting Person ** Regan William J.				2. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below)				
RO PLAC	E NORTH, SUIT		3. Date of Earliest Transaction (Month/Day/Year) 02/15/2013					SVP-Global Regulatory Strategy							
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)				_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by More than One Reporting Person							
											· omi med oy :	Tore than one i	aceporting 1 cison		
")	(State)	(Zip)			Tal	ole I -	Non-Deriv	vative Secu	rities A	cquired	, Disposed	of, or Bene	ficially Own	ied	
itle of Security 2. Transaction Date (Month/Day/Year				Date, if	ode	(.	A) or Dispo Instr. 3, 4 ar	sed of (and 5)	(D) Owi Tran			d	Ownership of Form: Direct (D) or Indirect	Beneficial Ownership	
						Cod	e V A			rice					
	Date	3A. Deemed Execution Date, if	4. Transac	s, ca	5. Numb Derivati	er of	options, co	osed of, or lonvertible stercisable and Date	Benefic ecuritiend 7.	cially Owes) Title and f Underly	vned d Amount	8. Price of Derivative	9. Number of Derivative	Ownersh	11. Nature
	-	r) (Instr. 8) Ac or of (In		Acquired (A) or Disposed of (D) (Instr. 3, 4,					ad 4)	(Instr. 5)	Beneficially Owned Following Reported Transaction(s	Derivative Security: Direct (D) or Indirects)			
			Code	V	(A)	(D)	Date Exercisab		n Ti	itle	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
\$ 3.08	02/15/2013		A		100,000	0	(1)	02/15/2	0231	ommon Stock	100,000	\$ 0	100,000	D	
1	OH 4301) Report on a 2. Conversion or Exercise Price of Derivative	(First) RO PLACE NORTH, SUIT (Street) OH 43017 (State) Report on a separate line for each conversion or Exercise Price of Derivative	Conversion or Exercise Price of Derivative Cirst (Middle) (Zip) (Zip) (Zip) (Zip) (Zip) (Zip) (Middle) (Zip) (Zip) (Zip) (Middle) (Zip) (Zip) (Middle)	NAVIE NAVI	NAVIDEA [NAVB]	NAVIDEA BIOPH [NAVB]	NAVIDEA BIOPHARM [NAVB]	NAVIDEA BIOPHARMACEUT [NAVB]	NAVIDEA BIOPHARMACEUTICALS, If [NAVB]	NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB] South of Earliest Transaction (Month/Day/Year)	NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB] X X X X X X X X X	Code V Amount Code C	NAVIDEA BIOPHARMACEUTICALS, INC. Check NAVB SVP-Globa	Code V Amount Code V Amount Code Ceg., puts, calls, warrants, options, convertible securities	Code V Amount Conversion Date Code, puts, calls, warrants, options Date Conversion Date Date

Daniel Community (Addison	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Regan William J. 425 METRO PLACE NORTH SUITE 450 DUBLIN, OH 43017			SVP-Global Regulatory Strategy				

Signatures

William J. Kelly, Jr., Attorney-In-Fact	02/19/2013
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option vests 25% per year beginning on the first anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.